What is the clinical evidence from this study?

Study design: Cohort. Population: Severe symptomatic aortic stenosis (n=41). Intervention: Transapical transcatheter aortic valve implantation (TA-TAVI). Primary outcome: 30-day mortality.

What question did this study set out to answer?

To evaluate the short-term and medium-term outcomes of transapical aortic valve replacement in high-risk patients.

January 1, 2015Polish Journal of Cardio-Thoracic SurgeryOpen Access

CARDIAC SURGERY Short-term and medium-term outcomes of transapical aortic valve implantation as a single-strategy approach: one center’s experience

View Full Paper

Ask AI

Bookmark

Key result

Transapical transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis resulted in a 30-day mortality rate of 17.1% and a 1-year survival rate of 77.3%.

Population

41 surgical high-risk or inoperable patients with severe symptomatic aortic stenosis, mean age 79.6 years…

Design

Case_series

Follow-up

30 days

Authors

JČJúlia ČanádyováNemocnice České Budějovice AMAleš MokráčekUniversity of South Bohemia in České Budějovice LPLadislav PešlNemocnice České Budějovice

Discussion

Member takes

Implication

Supports TA-TAVI feasibility in high-risk AS; extends single-center data but leaves open need for larger RCTs.

Key Points

To evaluate the short-term and medium-term outcomes of transapical aortic valve replacement in high-risk patients.
Conducted at a single center from June 2009 to December 2014 with 41 patients undergoing TA-TAVI.
All patients received balloon expandable Edwards SAPIEN valves as part of a clear transapical strategy.
30-day mortality rate was 17.1% with 7 patients deceased.
Complications included 1 stroke, 4 cases of re-exploration, and 4 cases of renal failure.
Postoperative ICU stay averaged 4.6 days and total hospitalization duration was 11.6 days.

Study Design

Type

Cohort (n=41)

Multicenter

Structured PICO

Population

41 high-risk or inoperable patients with severe symptomatic aortic stenosis undergoing transapical transcatheter aortic valve implantation, followed for a median of 12.7 months.

Intervention

Transapical transcatheter aortic valve implantation (TA-TAVI) using Edwards SAPIEN balloon expandable pericardial valves.

Outcome

30-day mortalityhard clinical

Transapical TAVI as a single-strategy approach is feasible for high-risk surgical patients, though associated with a 17.1% 30-day mortality in this early single-center experience.

Limitations

Small number of patients
Lack of a control group

Cite This Study

Čanádyová et al. (2015) conducted a cohort in Severe symptomatic aortic stenosis (n=41). Transapical transcatheter aortic valve implantation (TA-TAVI) was evaluated on 30-day mortality. Transapical transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis resulted in a 30-day mortality rate of 17.1% and a 1-year survival rate of 77.3%.

synapsesocial.com/papers/6a5ef63193a99557d97e3548 https://doi.org/10.5114/kitp.2015.52849

View Full Paper

Ask AI

Bookmark

CARDIAC SURGERY Short-term and medium-term outcomes of transapical aortic valve implantation as a single-strategy approach: one center’s experience

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Limitations

Cite This Study

CARDIAC SURGERY Short-term and medium-term outcomes of transapical aortic valve implantation as a single-strategy approach: one center’s experience

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider